Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]

Anton C van de Vusse, Suzanne G M Stomp-van den Berg, Alfons H F Kessels, Wim E J Weber, Anton C van de Vusse, Suzanne G M Stomp-van den Berg, Alfons H F Kessels, Wim E J Weber

Abstract

Background: Complex Regional Pain Syndrome type one (CRPS I) or formerly Reflex Sympathetic Dystrophy (RSD) is a disabling syndrome, in which a painful limb is accompanied by varying symptoms. Neuropathic pain is a prominent feature of CRPS I, and is often refractory to treatment. Since gabapentin is an anticonvulsant with a proven analgesic effect in various neuropathic pain syndromes, we sought to study the efficacy of the anticonvulsant gabapentin as treatment for pain in patients with CRPS I.

Methods: We did a randomized double blind placebo controlled crossover study with two three-weeks treatment periods with gabapentin and placebo separated by a two-weeks washout period. Patients started at random with gabapentin or placebo, which was administered in identical capsules three times daily. We included 58 patients with CRPS type 1.

Results: Patients reported significant pain relief in favor of gabapentin in the first period. Therapy effect in the second period was less; finally resulting in no significant effect combining results of both periods. The CRPS patients had sensory deficits at baseline. We found that this sensory deficit was significantly reversed in gabapentin users in comparison to placebo users.

Conclusions: Gabapentin had a mild effect on pain in CRPS I. It significantly reduced the sensory deficit in the affected limb. A subpopulation of CRPS patients may benefit from gabapentin.

Figures

Figure 1
Figure 1
Selection of patients participating in the trial
Figure 2
Figure 2
VAS for pain in both groups at start (T0), three weeks (T1), five weeks (T2), and eight weeks (T3) after randomization. T0-1 is the first treatment period, and T2-3 the second
Figure 3
Figure 3
Global perceived pain relief (on a seven-point scale) as reported by patients. GBP-1 and -2 denote patients receiving GBP in the first and second period; placebo-1 and -2 are analogously denoted.

References

    1. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: Prospective study of 829 patients. Lancet. 1993;342:1012–1016. doi: 10.1016/0140-6736(93)92877-V.
    1. Marchettini P, Lacerenza M, Ieracitano D, Canal N. Sensitized nociceptors in reflex sympathetic dystrophies. Funct Neurol. 1989;4:135–140.
    1. Mackin G. Medical and pharmacologic management of upper extremity neuropathic pain syndromes. J Hand Ther. 1997;10:96–109.
    1. Jänig W. The puzzle of "reflex sympathetic dystrophy": Mechanisms, hypotheses, open questions. In: Jänig W, Stanton-Hicks M, editor. Reflex sympathetic dystrophy. A reappraisal. 6 6. Seattle: IASP Press; 1996. pp. 1–24.
    1. Sindrup S, Jensen T. Pharmacologic treatment of pain in polyneuropathy. Neurology. 2000;55:915–920.
    1. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs. 2000;60:1029–1052.
    1. Pandey CK, Bose N, Garg G, Singh N, Baronia A, Agarwal A, Singh PK, Singh U. Gabapentin for the treatment of pain in guillain-barre syndrome: A double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95:1719–1723. doi: 10.1097/00000539-200212000-00046. table of contents.
    1. Serpell MG. Gabapentin in neuropathic pain syndromes: A randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557–566. doi: 10.1016/S0304-3959(02)00255-5.
    1. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA. 1998;280:1837–1842. doi: 10.1001/jama.280.21.1837.
    1. Tai Q, Kirshblum S, Chen B, Millis S, Johnston M, DeLisa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: A prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25:100–105.
    1. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: Systematic review of controlled and uncontrolled literature. Clin J Pain. 2001;17:284–295. doi: 10.1097/00002508-200112000-00002.
    1. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931–1937. doi: 10.1001/archinte.159.16.1931.
    1. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: A randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2002;27:481–486. doi: 10.1053/rapm.2002.35169.
    1. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology. 2002;59:1573–1579.
    1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. Jama. 1998;280:1831–1836. doi: 10.1001/jama.280.21.1831.
    1. Navani A, Rusy LM, Jacobson RD, Weisman SJ. Treatment of tremors in complex regional pain syndrome. J Pain Symptom Manage. 2003;25:386–390. doi: 10.1016/S0885-3924(02)00675-9.
    1. Stevens RA, Powar M, Stotz A, Barclay J, Kolbusz M. Gabapentin as an analgesic in crps, type i. Regional anesthesia and pain medicine. 1999;24:32. doi: 10.1016/S1098-7339(99)90209-2.
    1. Mellick GA, Mellick LB. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil. 1997;78:98–105. doi: 10.1016/S0003-9993(97)90020-4.
    1. Mellick GA, Mellicy LB, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage. 1995;10:265–266. doi: 10.1016/0885-3924(95)00071-6.
    1. Mellick LB, Mellick GA. Successful treatment of reflex sympathetic dystrophy with gabapentin. Am J Emerg Med. 1995;13:96. doi: 10.1016/0735-6757(95)90263-5.
    1. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol. 2003;42:491–495. doi: 10.1046/j.1365-4362.2003.01831.x.
    1. Jagustyn P, Romaniak A. [gabapentin – new therapeutic possibilities]. Neurol Neurochir Pol. 2002;36:971–980.
    1. Block F. [gabapentin for therapy of neuropathic pain]. Schmerz. 2001;15:280–288. doi: 10.1007/s004820100075.
    1. Block F. [gabapentin therapy for pain]. Nervenarzt. 2001;72:69–77. doi: 10.1007/s001150050717.
    1. Tong HC, Nelson VS. Recurrent and migratory reflex sympathetic dystrophy in children. Pediatr Rehabil. 2000;4:87–89.
    1. Rovetta G, Baratto L, Monteforte P. Low dose gabapentin for shoulder-hand syndrome induced by phenobarbital: A three-month study. Drugs Exp Clin Res. 1999;25:185–191.
    1. Wheeler DS, Vaux KK, Tam DA. Use of gabapentin in the treatment of childhood reflex sympathetic dystrophy. Pediatr Neurol. 2000;22:220–221. doi: 10.1016/S0887-8994(99)00139-3.
    1. Forouzanfar T, van Kleef M, Weber W. Radiofrequency lesions of the stellate ganglion in chronic pain syndromes: Retrospective analysis of clinical efficacy in 86 patients. Clin J Pain. 2000;16:164–168. doi: 10.1097/00002508-200006000-00010.
    1. Goris R. Treatment of reflex sympathetic dystrophy with hydroxyl radical scavengers. Unfallchirurg. 1985;88:330–332.
    1. Zyluk A. The reasons for poor response to treatment of posttraumatic reflex symptathetic dystrophy. Acta-Orthop-Belg. 1998;64:309–313.
    1. Koke AJ, Schouten JS, Lamerichs-Geelen MJ, Lipsch JS, Waltje EM, van Kleef M, Patijn J. Pain reducing effect of three types of transcutaneous electrical nerve stimulation in patients with chronic pain: A randomized crossover trial. Pain. 2004;108:36–42. doi: 10.1016/j.pain.2003.11.013.
    1. Merskey H, Bogduk N. Classification of chronic pain Descriptions of chronic pain syndromes and definitions of pain terms. 2. Seattle: IASP Press; 1994.
    1. Galer B, Jensen M. Development and preliminary validation of a pain measure specific to neuropathic pain: The neuropathic pain scale. Neurology. 1997;48:332–338.
    1. Kemler M, Schouten H, Gracely R. Diagnosing sensory abnormalities with either normal values or values from contralateral skin: Comparison of two approaches in complex regional pain syndrome i. Anesthesiology. 2000;93:718–727. doi: 10.1097/00000542-200009000-00021.
    1. Ochoa J, Yarnitzky D. Mechanical hyperalgesias in neuropathic pain patients: Dynamic and static subtypes. Ann Neurol. 1993;33:465–472.
    1. Oerlemans H, Oostendorp R, de Boo T, Perez R, Goris R. Signs and symptoms in complex regional pain syndrome type i/reflex sympathetic dystrophy: Judgment of the physician versus objective measurement. Clin J Pain. 1999;15:224–232. doi: 10.1097/00002508-199909000-00010.
    1. Arrindell W, Attema J. Scl-90 handleiding bij een multidimensionele psychopathologie indicatie. Lisse: Swets & Zeitlinger BV. 1986.
    1. Galer B, Henderson J, Perander J, Jensen M. Course of symptoms and quality of life measurement in complex regional pain syndrome: A pilot survey. J Pain Symptom Manage. 2000;20:286–292. doi: 10.1016/S0885-3924(00)00183-4.
    1. Schouten H. The mean difference between paired observations in crossover [het gemiddelde verschil tussen gepaarde waarnemingen in een kruisproef]. In: Bohn, Stafleu, van Loghem, editor. Een praktische inleiding in methodologie en analyse. 1995. pp. 79–83.
    1. Kemler MA, de Vet HC. Does randomization introduce bias in unblinded trials? Epidemiology. 2000;11:228. doi: 10.1097/00001648-200003000-00025.
    1. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996;347:143–147. doi: 10.1016/S0140-6736(96)90339-6.
    1. Fields H. Pain modulation: Expectation, opioid analgesia and virtual pain. Prog Brain Res. 2000;122:245–253.
    1. Chong M, Smith T, Hanna M. Case reports – reversal of sensory deficit associated with pain relief after treatment with gabapentin. Pain. 2002;96:329–333. doi: 10.1016/S0304-3959(01)00468-7.
    1. Verdugo R, Ochoa J. Reversal of hypoaesthesia by nerve block, or placebo: A psychologically mediated sign in chronic pseudoneuropathic pain patients. J Neurol Neurosurg Psychiatry. 1998;65:196–203.
    1. Filadora VA, 2nd, Sist TC, Lema MJ. Acute herpetic neuralgia and postherpetic neuralgia in the head and neck: Response to gabapentin in five cases. Reg Anesth Pain Med. 1999;24:170–174. doi: 10.1016/S1098-7339(99)90080-9.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться